RNS Number : 7464Z
N4 Pharma PLC
22 May 2019

22 May 2019

N4 Pharma Plc
("N4 Pharma" or the "Company")

Posting of Annual Report and Notice of AGM

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, announces that its Annual Report and Accounts for the year ended 31 December 2018 and Notice of the Annual General Meeting will be posted to shareholders later today, and are available on the Company's website at https://www.n4pharma.com.

The Company's Annual General Meeting will be held at 11.00 a.m. on 19 June 2019 at the offices of Allenby Capital Limited, 5 St Helen's Place, London EC3A 6AB.

For further information please contact:

Enquiries:

N4 Pharma Plc
Nigel Theobald, CEO — Via Scott PR

Allenby Capital Limited — Tel: +44(0)203 328 5656
James Reeve/Asha Chotai

Scott PR
Georgia Smith — Tel: +44(0)1477 539 539

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the

required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ACSBSGDUCDDBGCB